White House announces deals with Eli Lilly, Novo Nordisk to lower drug costs
The White House announced today that it reached agreements with Eli Lilly and Novo Nordisk to align their drug prices with the lowest paid by other developed nations, known as the most-favored-nation price. Like other recent agreements, Eli Lilly and Novo Nordisk will provide all state Medicaid programs access to MFN prices on their products and must offer medicines at deep discounts off the list price when selling directly to American consumers. In addition, Novo Nordisk committed to a $10 billion investment to expand its U.S. manufacturing capacity, while Eli Lilly announced it would provide at least $27 billion in new U.S. manufacturing investments.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services Nov. 5 published a final rule to codify the Medicare Drug Price Negotiation Program beginning in 2029. The…
Headline
The estimated average monthly premium for Medicare Part D stand-alone prescription drug plans is $51 for 2027, a 50% increase from $34 in 2026, for enrollees…
Headline
A new AHA blog examines a Department of Health and Human Services issue brief that claims Medicaid hospital provider taxes increase employer-sponsored…
Blog
A recent issue brief from the Department of Health and Human Services asserts that Medicaid hospital provider taxes raise employer-sponsored insurance premiums…
Headline
The U.S. District Court for the District of Massachusetts yesterday ruled in favor of 25 states and the District of Columbia to vacate the Centers for Medicare…
Headline
Extending Medicaid coverage by 12 months following childbirth increased use of postpartum care among mothers with pregnancy complications such as diabetes and…